LG Chem Acquires AVEO Oncology

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Astorg and Cinven Acquire LGC

November 21, 2019

Healthcare Services

A consortium led by private equity firms Astorg and Cinven has signed an agreement to acquire LGC, a UK-headquartered global leader in life sciences tools. The buyout will back LGC’s continued organic growth and M&A-led expansion across its standards, genomics and laboratory services businesses; financial terms were not disclosed and the transaction remains subject to regulatory approvals.

Amgen Acquires ChemoCentryx

August 4, 2022

Biotechnology

Amgen agreed to acquire ChemoCentryx for $52 per share in cash (approximately $3.7 billion enterprise value), gaining TAVNEOS (avacopan), a first-in-class oral therapy for ANCA-associated vasculitis. The deal, unanimously approved by both boards, is intended to strengthen Amgen's inflammation and nephrology portfolio and is expected to close following stockholder and regulatory approvals.

Agilent Technologies Acquires Avida Biomed

January 4, 2023

Biotechnology

Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.